Talisman
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 2
- Enrollment
- 130 patients (estimated)
- Sponsors
- Janssen Research & Development LLC
- Tags
- Bispecific Antibody, CD3, GPRC5D, Randomization
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 1950
- NCT Identifier
- NCT06500884
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.